Wharton's jelly mesenchymal stromal cells and derived extracellular vesicles as post-myocardial infarction therapeutic toolkit

Outstanding progress has been achieved in developing therapeutic options for reasonably alleviating symptoms and prolonging the lifespan of patients suffering from myocardial infarction (MI). Current treatments, however, only partially address the functional recovery of post-infarcted myocardium, wh...

Descripción completa

Detalles Bibliográficos
Autores: Muñoz-Domínguez, Noelia, Roura, Santiago|||0000-0003-4063-9661, Prat-Vidal, Cristina|||0000-0002-5621-1101, Vives Armengol, Joaquim|||0000-0001-9719-5235
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:251553
Acceso en línea:https://ddd.uab.cat/record/251553
https://dx.doi.org/urn:doi:10.3390/pharmaceutics13091336
Access Level:acceso abierto
Palabra clave:Biomanufacturing
Cardiac tissue engineering
Clinical translation
Extracellular vesicles
Mesenchymal stromal cells
Myocardial infarction
Wharton's jelly
Descripción
Sumario:Outstanding progress has been achieved in developing therapeutic options for reasonably alleviating symptoms and prolonging the lifespan of patients suffering from myocardial infarction (MI). Current treatments, however, only partially address the functional recovery of post-infarcted myocardium, which is in fact the major goal for effective primary care. In this context, we largely investigated novel cell and TE tissue engineering therapeutic approaches for cardiac repair, particu-larly using multipotent mesenchymal stromal cells (MSC) and natural extracellular matrices, from pre-clinical studies to clinical application. A further step in this field is offered by MSC-derived extracellular vesicles (EV), which are naturally released nanosized lipid bilayer-delimited particles with a key role in cell-to-cell communication. Herein, in this review, we further describe and discuss the rationale, outcomes and challenges of our evidence-based therapy approaches using Wharton's jelly MSC and derived EV in post-MI management.